Recombinant Human Echinoderm microtubule-associated protein-like 4 (EML4), partial

1. EML4-ALK fusion variant V3 is a high-risk feature for anaplastic lymphoma kinase-driven non-small cell lung cancer PMID: 29363116
2. The EML4-ALK fusion gene may be a strong oncogene in younger patients with lung adenocarcinoma. PMID: 29517858
3. lung adenocarcinoma in Asian patients aged 50 years, especially EML4-ALK and ROS1 fusion. Mutation analysis may be helpful in determining targeted therapy for the majority of these patients PMID: 30107055
4. Mutation testing at diagnosis is feasible in the vast majority of patients with Stage IV adenocarcinoma of the lung. Patients with EGFR or EML4ALK mutation and those who received pemetrexed maintenance had better clinical outcomes. PMID: 29199690
5. Our analysis indicated that ALK-EML4 positive non-small-cell lung cancers comprised a unique subgroup of adenocarcinomas with distinct clinicopathological characteristics. Incidence of ALK positivity was found to be higher in females and never smokers. PMID: 29199691
6. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors PMID: 27811184
7. identified EML4-ALK gene rearrangement in expanded circulating tumor cells from a patient with ALK-positive lung adenocarcinoma PMID: 27507192
8. Knockdown of SMYD2 as well as treatment with a SMYD2 inhibitor in two NSCLC cell lines with an EML4-ALK gene significantly attenuated the phosphorylation levels of the EML4-ALK protein. PMID: 28370702
9. The EML4-ALK-mediated upregulation of HIF1alpha, HK2 and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK-positive NSCLC cells. PMID: 27132509
10. We assessed the prevalence of EML4-ALK rearrangement gene measured by immunohistochemistry in an unselected population-based consecutive cohort of patients with adenocarcinoma of the lung (ACL), and the correlation with smoking history, thyroid transcription factor 1 (TTF1), gender and age PMID: 27943404
11. Our findings show that group EML4-ALK variants 3a/b in non-small cell lung cancer may be a major source of ALK inhibitor resistance in the clinic. PMID: 28039177
12. EML4-ALK rearrangement detection in malignant pleural effusions is a complementary method for EML4-ALK detection. VETANA and qRT-PCR are more appropriate for MPE detection. EML4-ALK rearrangement in pleural effusions has a predictive value for treatment. PMID: 27060609
13. EML4-ALK-positive lung cancer is often highly progressive. PMID: 26964537
14. case report in which the EML4-ALK fusion gene was identified as a second primary lung cancer after surgically resecting EGFR mutation-positive adenocarcinoma PMID: 26704814
15. 79 (69%) were negative for echinoderm microtubule-associated protein like 4 (EML4)-ALK translocation, nine (8%) were positive and 27 (23%) were unevaluable. PMID: 25757141
16. Data suggest that platelets are a valuable source for the non-invasive detection of echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements and for predicting and monitoring outcome to crizotinib. PMID: 26544515
17. Data show that inhibition of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK)-mediated stem-like properties enhances the anti-tumor effect. PMID: 26517679
18. This review describes the biology of EML4 and ALK, explains the main features of EML4-ALK fusion proteins and outline the therapies that target EML4-ALK in cancer. [review] PMID: 26755435
19. We further showed that both EML4-ALK and mutant forms of EGFR modulate PD-L1 expression via common downstream pathways mediated by MEK-ERK and by PI3K-AKT. PMID: 26019170
20. EGFR gene mutations and the EML4-ALK fusion gene were detected in 92 lung adenocarcinoma patients in China. PMID: 24935562
21. In the absence of EML4, NUDC was no longer able to localize to the mitotic spindle, whereas NUDC was dispensable for EML4 localization. PMID: 25789526
22. It was revealed that the EML4-ALK fusion gene was observed predominantly in adenocarcinoma, non-smoking and non-small-cell lung cancers (NSCLC) patients, especially those diagnosed in the advanced clinical stage of NSCLC. PMID: 25706305
23. Results suggested that chromothripsis may be a mechanism of oncogenic rearrangement of EML4-ALK. PMID: 25144242
24. The FISH-based method of detecting EML4-ALK rearrangement in lung cancer may miss a significant number of patients who could benefit from targeted ALK therapy. IHC should be strongly considered, and NGS is recommended in borderline cases. PMID: 25721120
25. H1299 NSCLC cells stably expressing EML4-ALK acquire epithelial-mesenchymal transition (EMT) phenotype, associated with enhanced invasive migration and increased expression of EMT-inducing transcription factors. PMID: 25735977
26. Results suggest that heat shock protein 90 (Hsp90) inhibitors may overcome ligand-triggered resistance in microtubule associated protein-like 4 (EML4)--anaplastic lymphoma kinase (ALK) lung cancer cells. PMID: 24952482
27. EML4 genetic translocation is a therapeutic target in the treatment of aggressive papillary cancer of the thyroid. PMID: 24633422
28. Letter/Case Report: lung adenocarcinoma where EML4-ALK gene rearrangement was missed by FISH techniques but detected using reverse transcriptase PCR. PMID: 25028527
29. EML4-ALK gene rearrangements do not appear to be involved in the development of primary adenocarcinoma of the urinary bladder. PMID: 23887300
30. EML4-ALK fusion genepositivitymightbe higher inyoungerNSCLCpatientswithwild-type EGFR. PMID: 24388371
31. EML4-ALK fusion is uncommon, reported in about 5% of NSCLC patients. PMID: 24346098
32. NSCLC patients with the EML4-ALK fusion gene might be relatively insensitivite to cytotoxic chemotherapy. PMID: 24982409
33. Hsp90-sensitive EML4-ALK variants are exceptions to the rule that oncogenic fusion proteins involve breakpoints in disordered regions of both partners PMID: 24706829
34. The first report concerning the presence of the EML4-ALK fusion gene in a sarcomatoid carcinoma of the lung. PMID: 23664446
35. evaluated mutations in four driver genes, epidermal growth factor receptor (EGFR), Kirsten ras oncogene (KRAS), c-MET, and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), in Chinese lung adenocarcinoma patients PMID: 23919423
36. This case suggests that echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion is an oncogenic event in not only carcinomas but also sarcomas originating from stromal cells. PMID: 24277751
37. EML4-ALK rearrangement is associated with congenital pulmonary airway malformation. PMID: 23357247
38. EML4-ALK rearrangements are associated with lung carcinomas. PMID: 23408463
39. EML4-ALK rearrangement is associated with response to therapy in lung adenocarcinoma. PMID: 23486270
40. variations in EML4-ALK fusion is associated with small-cell lung cancer with adenocarcinoma. PMID: 23154565
41. EML4-ALK fusion variant is associated with non-small-cell lung cancer. PMID: 23169500
42. Lung neoplasm patients who harbor EML4-ALK fusion genes generally have wild type EGFR and KRAS genes. PMID: 22736493
43. EML4-ALK variant is associated with lung cancer. PMID: 22706607
44. EML4-ALK-variations are associated with non-small cell lung cancer. PMID: 22722791
45. EML4-ALK and low thymidylate synthase expression is associated with treatment outcome with pemetrexed in Non-Small Cell Lung Cancer. PMID: 22056890
46. EML4-anaplastic lymphoma kinase (ALK) fusion gene is associated with longer overall survival of lung adenocarcinoma patients with wild-type epidermal growth factor receptor mutations. PMID: 22124476
47. frequent rearrangement in lung signet-ring cell carcinoma PMID: 21036415
48. New molecular targets are on investigation, such as EML4-ALK translocation. PMID: 21420271
49. EML4-ALK fusion variants have a role in non-small cell lung cancer PMID: 21356191
50. EML4-ALK fusion appears to be tightly associated with ALK mRNA expression levels. RACE-coupled PCR sequencing is a highly sensitive method that could be used clinically for the identification of EML4-ALK-positive patients PMID: 20624322

Show More

Hide All

HGNC: 1316

OMIM: 607442

KEGG: hsa:27436

STRING: 9606.ENSP00000320663

UniGene: Hs.713173